FDA Names Seven Participants to Precheck Program

The FDA has selected seven pharmaceutical companies to participate in its new PreCheck Pilot Program, an initiative designed to accelerate domestic manufacturing capacity through early regulatory engagement. Launched in early 2026, the program aims to strengthen U.S. supply chain resilience by providing guidance as companies build new production facilities for critical therapies. This selection marks a significant step in aligning federal manufacturing policy with the industry's shift toward domestic infrastructure for advanced modalities like GLP-1s and cell and gene therapies.

The FDA's PreCheck Pilot Program, established in February 2026 following an Executive Order, has officially named its first seven participants: Eli Lilly, Regeneron, Amneal Pharmaceuticals, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics, and Kyowa Kirin. Out of more than 80 applicants, these companies were chosen to receive earlier regulatory interaction intended to de-risk and speed up the construction of domestic manufacturing sites. The initiative is a direct response to federal mandates to bolster the U.S. pharmaceutical supply chain and reduce reliance on foreign production by streamlining the path from facility construction to operational readiness.

The selected projects represent a diverse range of therapeutic modalities and involve significant capital investments across the United States. Notable facilities included in the pilot are Eli Lilly’s drug-substance site in Lebanon, Indiana, which is dedicated to GLP-1 production, and Regeneron’s $2 billion biologics facility in Saratoga Springs, New York. Additionally, the participation of Cellares, Kriya Therapeutics, and Kyowa Kirin underscores a specific regulatory priority on scaling manufacturing footprints for complex cell and gene therapies as well as rare disease treatments.

Beyond manufacturing logistics, the industry is navigating a broader shift toward the concept of "healthspan," which is moving from academic circles into mainstream consumer demand. This trend is pressuring pharmaceutical companies to pivot their value propositions from reactive disease treatment toward proactive longevity-oriented care, a move that will likely reshape R&D prioritization and commercial engagement models in the coming years. Simultaneously, the sector is seeing the rise of new geographic hubs like Las Vegas, which is being positioned as a credible, cost-effective alternative to traditional coastal biotech centers due to its business-friendly environment and increasing access to venture capital.